发明名称 |
Agent and methods for reducing inflammatory markers |
摘要 |
A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum. A TNF-α inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof. |
申请公布号 |
US8741847(B2) |
申请公布日期 |
2014.06.03 |
申请号 |
US201213463851 |
申请日期 |
2012.05.04 |
申请人 |
|
发明人 |
Chez Michael |
分类号 |
A61K38/00;C07K16/00 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for treating an autism spectrum disorder or pervasive development disorder, comprising:
administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum disorder or pervasive development disorder and an elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in serum; and lowering the elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in the serum, wherein the TNF-α inhibiting agent is selected from the group consisting of lenalinomide; thalidomide; I-carnosine; infliximab; etanercept; and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-α inhibiting agent.
|
地址 |
|